We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Protective Immunity Against SARS-CoV-2 Short-Lived as Seasonal Coronavirus Can Reinfect People Every Year

By HospiMedica International staff writers
Posted on 16 Sep 2020
Illustration
Illustration
New research studying immunity to coronaviruses similar to SARS-CoV-2 suggests that the duration of protective immunity against the novel coronavirus may be short-lived and COVID-19 is likely to become seasonal.

There is limited evidence of re-infection after exposure to SARS-CoV-2, although re-infection by coronaviruses is widely believed to occur, according to a report by Medical Xpress. In order to understand the length of immunity to re-infection so as to prepare for future waves of SARS-CoV-2 infection, researchers examined four strains of human seasonal coronavirus - HCoV-NL63, HCoV-229E, HCoV-OC43 and HCoV-HKU1 - that cause respiratory tract infections. The team led by Dr. Lia van der Hoek, of Amsterdam University Medical Center (Amsterdam, The Netherlands) attempted to find out how often seasonal coronavirus infections occur by examining 513 serum samples of 10 healthy adult males that were collected at regular intervals since the 1980s. The researchers measured the increases in antibodies to the nucleocapsid protein - an abundant coronavirus protein - for each seasonal coronavirus with an increase in antibodies being considered as a new infection.

The team found three to 17 coronavirus infections per patient, with re-infection times between six and 105 months. The researchers found frequent re-infections at 12 months after the initial infection. Additionally, blood samples collected in the Netherlands during the months of June, July, August and September showed the lowest rate of infections for all four seasonal coronaviruses, indicating higher frequency of infections during winter in temperate countries. The researchers believe that SARS-CoV-2 could follow a similar pattern after the pandemic.

Another study has suggested that the novel coronavirus will become a seasonal virus in countries with temperate climates once herd immunity is attained, although COVID-19 will continue to spread across the seasons until then. The study authors have noted that similar to SARS-CoV-2, other respiratory viruses also follow seasonal patterns, particularly in temperate regions. However, COVID-19 has a higher rate of transmission than other respiratory viruses such as the flu, and hence, unlike the flu and other respiratory viruses, the factors governing seasonality of viruses will be unable to halt the spread of COVID-19 in the summer months. Nevertheless, the transmission rate of COVID-19 should decline significantly once herd immunity is achieved through natural infections and vaccinations, making the SARS-CoV-2 virus more susceptible to seasonal factors.

“COVID-19 is here to stay and it will continue to cause outbreaks year-round until herd immunity is achieved,” warned study senior author Hassan Zaraket from the American University of Beirut (Beirut, Lebanon). “Therefore, the public will need to learn to live with it, and continue practicing the best prevention measures, including wearing of masks, physical distancing, hand hygiene, and avoidance of gatherings.”

Related Links:
Amsterdam University Medical Center
The American University of Beirut


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Pressure Guidewire
SavvyWire
New
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+

Channels

Surgical Techniques

view channel
Image: The novel approach combining MRI, fluid dynamics, and custom algorithms predicts brain cancer recurrence sites (photo courtesy of AdobeStock)

Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next

Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more